{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:37:17Z","timestamp":1776868637276,"version":"3.51.2"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.antiviral.2022.105384","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T23:00:07Z","timestamp":1658185207000},"page":"105384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Antiviral effect of vesatolimod (GS-9620) against foot-and-mouth disease virus both in vitro and in vivo"],"prefix":"10.1016","volume":"205","author":[{"given":"Gyeongmin","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo Rin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aro","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Hyeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Ja","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9242-2731","authenticated-orcid":false,"given":"Su-Mi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2022.105384_bib1","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/jvh.12942","article-title":"Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment","volume":"25","author":"Agarwal","year":"2018","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2022.105384_bib2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0042-6822(03)00144-2","article-title":"Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis","volume":"311","author":"Airaksinen","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2022.105384_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9975(03)00041-0","article-title":"The pathogenesis and diagnosis of foot-and-mouth disease","volume":"129","author":"Alexandersen","year":"2003","journal-title":"J. Comp. Pathol."},{"key":"10.1016\/j.antiviral.2022.105384_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01369-16","article-title":"TLR7 agonist GS-9620 is a potent inhibitor of acute HIV-1 infection in human peripheral blood mononuclear cells","volume":"61","author":"Bam","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2022.105384_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.05.013","article-title":"Evolution of Toll-like receptor 7\/8 agonist therapeutics and their delivery approaches: from antiviral formulations to vaccine adjuvants","volume":"175","author":"Bhagchandani","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.antiviral.2022.105384_bib6","first-page":"7122","article-title":"Tissue expression of Toll-like receptors 2, 3, 4 and 7 in swine in response to the Shimen strain of classical swine fever virus","volume":"17","author":"Cao","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.antiviral.2022.105384_bib7","doi-asserted-by":"crossref","first-page":"7799","DOI":"10.1128\/jvi.71.10.7799-7803.1997","article-title":"Interleukin-12 exhibits potent antiviral activity in experimental herpesvirus infections","volume":"71","author":"Carr","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105384_bib8","doi-asserted-by":"crossref","first-page":"61958","DOI":"10.18632\/oncotarget.18740","article-title":"Swine IRF3\/IRF7 attenuates inflammatory responses through TLR4 signaling pathway","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.antiviral.2022.105384_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016333","article-title":"Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant","volume":"6","author":"Coler","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2022.105384_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41541-018-0057-5","article-title":"The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial","volume":"3","author":"Coler","year":"2018","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.antiviral.2022.105384_bib11","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20160170","article-title":"Effects of porcine MyD88 knockdown on the expression of TLR4 pathway-related genes and proinflammatory cytokines","volume":"36","author":"Dai","year":"2016","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.antiviral.2022.105384_bib12","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1089\/jir.2012.0012","article-title":"Antiviral therapeutics to control foot-and-mouth disease","volume":"32","author":"Dias","year":"2012","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.antiviral.2022.105384_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.668890","article-title":"Use of protein pegylation to prolong the antiviral effect of IFN against FMDV","volume":"12","author":"Diaz-San Segundo","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.antiviral.2022.105384_bib14","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1128\/JVI.01874-09","article-title":"Interferon-induced protection against foot-and-mouth disease virus infection correlates with enhanced tissue-specific innate immune cell infiltration and interferon-stimulated gene expression","volume":"84","author":"Diaz-San Segundo","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105384_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4049\/immunohorizons.1700063","article-title":"Recent advances in the discovery and delivery of TLR7\/8 agonists as vaccine adjuvants","volume":"2","author":"Dowling","year":"2018","journal-title":"Immunohorizons"},{"key":"10.1016\/j.antiviral.2022.105384_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02417-17","article-title":"TLR7 agonists display potent antiviral effects against norovirus infection via innate stimulation","volume":"62","author":"Enosi Tuipulotu","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2022.105384_bib17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1124\/jpet.113.207878","article-title":"Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses","volume":"348","author":"Fosdick","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.antiviral.2022.105384_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134640","article-title":"The imidazoquinoline Toll-like receptor-7\/8 agonist hybrid-2 potently induces cytokine production by human newborn and adult leukocytes","volume":"10","author":"Ganapathi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2022.105384_bib19","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2015.02.037","article-title":"The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection","volume":"63","author":"Gane","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105384_bib20","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1021\/jm049211v","article-title":"Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production","volume":"48","author":"Gerster","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2022.105384_bib21","first-page":"9","article-title":"An antiviral mechanism investigated with ribavirin as an RNA virus mutagen for foot-and-mouth disease virus","volume":"39","author":"Gu","year":"2006","journal-title":"J. Biochem. Mol. Biol."},{"key":"10.1016\/j.antiviral.2022.105384_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2796.2008.02050.x","article-title":"Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications","volume":"265","author":"Guiducci","year":"2009","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.antiviral.2022.105384_bib23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.immuni.2006.08.009","article-title":"Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors","volume":"25","author":"Honda","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.antiviral.2022.105384_bib24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12967-020-02275-2","article-title":"A novel TLR7 agonist as adjuvant to stimulate high quality HBsAg-specific immune responses in an HBV mouse model","volume":"18","author":"Hu","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.antiviral.2022.105384_bib25","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3390\/vaccines9040308","article-title":"A vaccine strain of the A\/ASIA\/Sea-97 lineage of foot-and-mouth disease virus with a single amino acid substitution in the P1 region that is adapted to suspension culture provides high immunogenicity","volume":"9","author":"Hwang","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.antiviral.2022.105384_bib26","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41598-020-80896-9","article-title":"Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2","volume":"11","author":"Jang","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2022.105384_bib27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","volume":"68","author":"Janssen","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105384_bib28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.smim.2006.12.004","article-title":"TLR signaling","volume":"19","author":"Kawai","year":"2007","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.antiviral.2022.105384_bib29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.antiviral.2014.01.014","article-title":"A recombinant adenovirus bicistronically expressing porcine interferon-\u03b1 and interferon-\u03b3 enhances antiviral effects against foot-and-mouth disease virus","volume":"104","author":"Kim","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105384_bib30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.antiviral.2010.06.004","article-title":"Multiple shRNAs driven by U6 and CMV promoter enhances efficiency of antiviral effects against foot-and-mouth disease virus","volume":"87","author":"Kim","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105384_bib31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.antiviral.2012.09.009","article-title":"Enhanced inhibition of foot-and-mouth disease virus by combinations of porcine interferon-\u03b1 and antiviral agents","volume":"96","author":"Kim","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105384_bib32","doi-asserted-by":"crossref","first-page":"8267","DOI":"10.1128\/JVI.00766-15","article-title":"Robust protection against highly virulent foot-and-mouth disease virus in swine by combination treatment with recombinant adenoviruses expressing porcine alpha and gamma interferons and multiple small interfering RNAs","volume":"89","author":"Kim","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105384_bib33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.vetmic.2018.12.023","article-title":"Chimeric vaccine strain of type O foot-and-mouth disease elicits a strong immune response in pigs against ME-SA and SEA topotypes","volume":"229","author":"Ko","year":"2019","journal-title":"Vet. Microbiol."},{"key":"10.1016\/j.antiviral.2022.105384_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156110","article-title":"Complexities in isolation and purification of multiple viruses from mixed viral infections: viral interference, persistence and exclusion","volume":"11","author":"Kumar","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2022.105384_bib35","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2022.105384_bib36","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3851\/IMP2845","article-title":"Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C","volume":"20","author":"Lawitz","year":"2015","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2022.105384_bib37","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.3389\/fimmu.2019.02509","article-title":"Mincle and STING-stimulating adjuvants elicit robust cellular immunity and drive long-lasting memory responses in a foot-and-mouth disease vaccine","volume":"10","author":"Lee","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.antiviral.2022.105384_bib38","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.molimm.2020.02.018","article-title":"Enhanced efficacy of a multi-epitope vaccine for type A and O foot-and-mouth disease virus by fusing multiple epitopes with Mycobacterium tuberculosis heparin-binding hemagglutinin (HBHA), a novel TLR4 agonist","volume":"121","author":"Lei","year":"2020","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.antiviral.2022.105384_bib39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.intimp.2018.03.022","article-title":"Antiviral activity of porcine interferon delta 8 against foot-and-mouth disease virus in vitro","volume":"59","author":"Li","year":"2018","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.antiviral.2022.105384_bib40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12929-019-0585-y","article-title":"Hypoxia and therapeutic treatment of EV-A71 with an immune modulator TLR7 agonist in a new immunocompetent mouse model","volume":"26","author":"Liou","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.antiviral.2022.105384_bib41","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3851\/IMP2548","article-title":"Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist","volume":"18","author":"Lopatin","year":"2013","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2022.105384_bib42","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2014.12.026","article-title":"Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B","volume":"62","author":"Menne","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105384_bib43","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fimmu.2020.00406","article-title":"Lipidated imidazoquinoline TLR7\/8 adjuvants elicit influenza-specific Th1 immune responses and protect against heterologous H3N2 influenza challenge in mice","volume":"11","author":"Miller","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.antiviral.2022.105384_bib44","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1128\/JVI.02775-06","article-title":"Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons","volume":"81","author":"Moraes","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105384_bib45","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.it.2005.06.009","article-title":"TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway","volume":"26","author":"Moynagh","year":"2005","journal-title":"Trends Immunol."},{"key":"10.1016\/j.antiviral.2022.105384_bib46","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1017\/S0022172400070625","article-title":"Guanidine and heat sensitivity of foot-and-mouth disease virus (FMDV) strains","volume":"89","author":"Nettleton","year":"1982","journal-title":"J. Hyg."},{"key":"10.1016\/j.antiviral.2022.105384_bib47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41541-017-0043-3","article-title":"Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial","volume":"3","author":"Pillet","year":"2018","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.antiviral.2022.105384_bib48","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5501\/wjv.v5.i2.85","article-title":"Determination of 50% endpoint titer using a simple formula","volume":"5","author":"Ramakrishnan","year":"2016","journal-title":"World J. Virol."},{"key":"10.1016\/j.antiviral.2022.105384_bib49","doi-asserted-by":"crossref","first-page":"8809","DOI":"10.1128\/JVI.00800-16","article-title":"Constitutively active IRF7\/IRF3 fusion protein completely protects swine against foot-and-mouth disease","volume":"90","author":"Ram\u00edrez-Carvajal","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105384_bib50","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.vetmic.2018.05.015","article-title":"Synthetic RNA derived from the foot-and-mouth disease virus genome elicits antiviral responses in bovine and porcine cells through IRF3 activation","volume":"221","author":"Rodr\u00edguez Pulido","year":"2018","journal-title":"Vet. Microbiol."},{"key":"10.1016\/j.antiviral.2022.105384_bib51","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1158\/2326-6066.CIR-14-0202","article-title":"Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma","volume":"3","author":"Sabado","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.antiviral.2022.105384_bib52","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.virusres.2012.07.005","article-title":"Selection and characterisation of guanidine-resistant mutants of human enterovirus 71","volume":"169","author":"Sadeghipour","year":"2012","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2022.105384_bib53","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0264-410X(97)86180-4","article-title":"Emergency vaccination of pigs against foot-and-mouth disease: protection against disease and reduction in contact transmission","volume":"16","author":"Salt","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2022.105384_bib54","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1021\/jm100358c","article-title":"Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues","volume":"53","author":"Shukla","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2022.105384_bib55","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","article-title":"The JAK-STAT pathway at twenty","volume":"36","author":"Stark","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.antiviral.2022.105384_bib56","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.4049\/jimmunol.1300787","article-title":"Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion","volume":"191","author":"Tel","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2022.105384_bib57","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1089\/jir.2008.0058","article-title":"Activation of porcine natural killer cells and lysis of foot-and-mouth disease virus infected cells","volume":"29","author":"Toka","year":"2009","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.antiviral.2022.105384_bib58","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.antiviral.2017.01.018","article-title":"Antiviral activity of ovine interferon tau 4 against foot-and-mouth disease virus","volume":"143","author":"Usharani","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105384_bib59","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1161\/CIRCRESAHA.108.192179","article-title":"CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis","volume":"104","author":"Yuan","year":"2009","journal-title":"Circ. Res."},{"key":"10.1016\/j.antiviral.2022.105384_bib60","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2018.02.002","article-title":"GS-9620 inhibits enterovirus 71 replication mainly through the NF-\u03baB and PI3K-AKT signaling pathways","volume":"153","author":"Zhang","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105384_bib61","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1746-6148-10-2","article-title":"Resiquimod and polyinosinic-polycytidylic acid formulation with aluminum hydroxide as an adjuvant for foot-and-mouth disease vaccine","volume":"10","author":"Zhou","year":"2014","journal-title":"BMC Vet. Res."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635422200153X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635422200153X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:35:45Z","timestamp":1759062945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635422200153X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":61,"alternative-id":["S016635422200153X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2022.105384","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral effect of vesatolimod (GS-9620) against foot-and-mouth disease virus both in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2022.105384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105384"}}